Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EDIT Editas Medicine

Not Yet Opened 09-29 16:00:00 EDT

2.59

+0.08

+3.19%

盘后2.60

+0.01+0.39%

19:40 EDT

High2.62	Low2.51	Vol1.57M
Open2.54	D1 Closing2.51	Amplitude4.38%
Mkt Cap396.27M	Tradable Cap297.85M	Total Shares153.00M
T/O4.04M	T/O Rate1.36%	Tradable Shares115.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EDIT","market":"US","secType":"STK","nameCN":"Editas Medicine","latestPrice":2.59,"timestamp":1790712000000,"preClose":2.51,"halted":0,"volume":1569545,"hourTrading":{"tag":"盘后","latestPrice":2.6,"preClose":2.59,"latestTime":"19:40 EDT","volume":17640,"amount":45714.4202,"timestamp":1790725226279,"change":0.01,"changeRate":0.003861,"amplitude":0.007722},"delay":0,"changeRate":0.0318725099601594,"floatShares":114999999,"shares":153000000,"eps":-0.730719,"marketStatus":"Not Yet Opened","change":0.08,"latestTime":"09-29 16:00:00 EDT","open":2.54,"high":2.62,"low":2.51,"amount":4042906.2100699996,"amplitude":0.043825,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.730719,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790755200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.51,"preHourTrading":{"tag":"盘前","latestPrice":2.59,"preClose":2.51,"latestTime":"09:25 EDT","volume":1041,"amount":2651.779899,"timestamp":1790688318268,"change":0.08,"changeRate":0.031873,"amplitude":0.035857},"postHourTrading":{"tag":"盘后","latestPrice":2.6,"preClose":2.59,"latestTime":"19:40 EDT","volume":17640,"amount":45714.4202,"timestamp":1790725226279,"change":0.01,"changeRate":0.003861,"amplitude":0.007722},"volumeRatio":0.510366,"impliedVol":1.0604,"impliedVolPercentile":0.4701},"requestUrl":"/m/hq/s/EDIT/wiki","defaultTab":"wiki","newsList":[{"id":"2669435367","title":"Editas slips amid pressure on gene-editing sector after Anthropic update","url":"https://stock-news.laohu8.com/highlight/detail?id=2669435367","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669435367?lang=en_us&edition=fundamental","pubTime":"2026-09-24 02:55","pubTimestamp":1790189712,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) is trading lower alongside other gene editing peers after Anthropic shared early findings on a CRISPR like enzyme system. An...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-slips-amid-pressure-on-gene-editing-sector-after-anthropic-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-slips-amid-pressure-on-gene-editing-sector-after-anthropic-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4611","BK4588","GNMX","BK4139","CRSP","LU1861558580.USD","IDNA","HELX","SYNB","BK4556","LU1861559042.SGD","ARKG","WDNA","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669048573","title":"Editas Medicine Raised to Buy from Neutral by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2669048573","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669048573?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:39","pubTimestamp":1790167140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EDIT/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669007891","title":"Guggenheim Upgrades Editas Medicine to Buy From Neutral, Price Target is $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2669007891","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669007891?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:09","pubTimestamp":1790161752,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) has an average rating of overweight and mean price target of $4.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641500","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641500","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667641500?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:12","pubTimestamp":1789470776,"startTime":"0","endTime":"0","summary":"Advasa  shares were up more than 49% in Tuesday's premarket activity, rebounding from a 58% loss in the previous session.Vera Therapeutics  stock was over 14% higher after the company said its kidney disease drug met all prespecified endpoints in a phase 3 trial final efficacy analysis.Radiant Logistics  shares were up 13% after the company reported higher fiscal Q4 adjusted earnings and revenue.Editas Medicine  stock was 9% higher after a 1.5% advance in the prior day's session.Eltek  shares were up 7%, extending Monday's 10% rise.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VERA","BK4023","EDIT","BK4148","BK4585","BK4539","LU2324357040.USD","BK4131","BK4139","ADBT","ELTK","RLGT","BK4556","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666453032","title":"Editas Medicine EVP, Chief Medical Officer Daniel Ory Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666453032","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666453032?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:25","pubTimestamp":1788985521,"startTime":"0","endTime":"0","summary":"Editas Medicine EVP, Chief Medical Officer Daniel Ory files initial beneficial ownership statementEditas Medicine filed a Form 3 naming Daniel Ory as EVP, chief medical officer, dated Sept. 8, 2026.Di","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL2MS6p2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666383535","title":"Editas Grants New CMO Daniel Ory Stock Options for 950,000 Shares at USD 3.03 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2666383535","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666383535?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:02","pubTimestamp":1788958923,"startTime":"0","endTime":"0","summary":"Editas grants new CMO Daniel Ory stock options for 950,000 shares at USD 3.03 eachEditas Medicine granted new Chief Medical Officer Daniel Ory stock options for 950,000 shares, priced at USD 3.03 per ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDLbmgnFk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","EDIT","IE00BKPKM429.USD","BK4556","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BQXX3D17.EUR","SG9999014021.USD","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","BK4585","BCDF","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","BK4139","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","BK4588","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533041","title":"Press Release: Editas Medicine Reports Inducement Grants to New Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533041","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533041?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:00","pubTimestamp":1788958800,"startTime":"0","endTime":"0","summary":"ir@editasmed.com. media@editasmed.com","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732264","title":"Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732264","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732264?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:01","pubTimestamp":1788865260,"startTime":"0","endTime":"0","summary":"Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical developmentAppointment strengthens executive leadership team as Editas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASCI","BK4556","IE0031619046.USD","IE00B66KJ199.SGD","SYNB","IDNA","WDNA","BK4585","IE00B7SZL793.SGD","BK4214","BK4588","GNMX","BK4139","HELX","IE00B19Z4B17.USD","AAP","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322562","title":"Editas Medicine Appoints Dan Ory, M.d., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322562?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA8HHBTT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EDIT","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664851760","title":"Editas Medicine to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664851760","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664851760?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:00","pubTimestamp":1788267600,"startTime":"0","endTime":"0","summary":"ir@editasmed.com. media@editasmed.com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354208/0/en/editas-medicine-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4139","SYNB","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883078","title":"Editas Medicine Files $400 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883078","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883078?lang=en_us&edition=fundamental","pubTime":"2026-09-01 05:15","pubTimestamp":1788210958,"startTime":"0","endTime":"0","summary":"Editas Medicine  filed a registration statement Monday with the US Securities and Exchange Commission for the potential sale of up to $400 million in securities.The filing covers debt securities, common and preferred stock, depositary shares, subscription rights, purchase contracts, warrants, and units.Net proceeds will be used for general corporate purposes, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664839008","title":"Editas Medicine files $400M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2664839008","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664839008?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:30","pubTimestamp":1788208221,"startTime":"0","endTime":"0","summary":"16:27 EDT Editas Medicine (EDIT) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-medicine-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-medicine-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883801","title":"Editas Medicine - May Offer up to $400 Mln of Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883801?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:26","pubTimestamp":1788207971,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EDIT","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003614","title":"Acrivon Therapeutics Names Michaela Levin Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003614","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003614?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:31","pubTimestamp":1788179470,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics names Michaela Levin chief business officerAcrivon Therapeutics appointed Michaela Levin as chief business officer, effective Aug. 31, 2026.Levin most recently served as vice pres","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLbvKJy4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","BK4585","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4556","BK4588","BK4112","ACRV","BK4139","IE00BQXX3C00.GBP","IE00BKPKM429.USD","IE00BQXX3D17.EUR","SG9999014039.USD","OVID","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BQXX3F31.USD","SG9999014021.USD","IE00B3QW5Z07.USD","EDIT","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014005.SGD","NDAQ","IE00BN0W2T93.GBP","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660467429","title":"Editas Medicine Initiated at Buy by Ladenburg Thalmann","url":"https://stock-news.laohu8.com/highlight/detail?id=2660467429","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660467429?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:58","pubTimestamp":1787057880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EDIT/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EDIT","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660951461","title":"Ladenburg Thalmann Initiates Editas Medicine at Buy With $6 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2660951461","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660951461?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:01","pubTimestamp":1787050914,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) has an average rating of overweight and mean price target of $6, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658593567","title":"Editas Medicine, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658593567","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658593567?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:59","pubTimestamp":1786363182,"startTime":"0","endTime":"0","summary":"Editas Medicine, Inc. reports results for the quarter ended June 30 - Earnings SummaryEditas Medicine, Inc.EDIT.OQreported a quarterly adjusted loss of 15 cents per share for the quarter ended June 30","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N4470RH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EDIT","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657262941","title":"Editas Medicine Director Ellinor Patrick Thomas II Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657262941","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657262941?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:16","pubTimestamp":1786137389,"startTime":"0","endTime":"0","summary":"Editas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statementEditas Medicine filed a Form 3 showing director Ellinor Patrick Thomas II as a reporting owner, dated Aug. 6.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL63cxB4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EDIT","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644491","title":"Editas Medicine, Inc. Expected to Post a Loss of 27 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644491","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657644491?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:33","pubTimestamp":1786113186,"startTime":"0","endTime":"0","summary":"Editas Medicine, Inc. <EDIT.OQ> expected to post a loss of27cents a share - Earnings PreviewEditas Medicine, Inc.EDIT.OQEDIT.Ois expected to  show a fall in quarterly revenue when it reports  results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657560633","title":"Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657560633","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657560633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:20","pubTimestamp":1786015252,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Q2 collaboration revenue falls, net loss widensOverviewU.S. gene editing firm's Q2 collaboration revenue fell yr/yr due to lower Regeneron revenueQ2 net loss widened from prior y","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","LU0889565916.HKD","LU1861558580.USD","BK4556","LU2362541273.HKD","BK4139","LU2237438978.USD","LU2362540622.SGD","LU0823416689.USD","PGEN","LU2468319806.SGD","BK4585","LU2362541513.USD","ARKG","LU0289739699.SGD","NTLA","LU0882574055.USD","LU2106854487.HKD","LU1861559042.SGD","LU2023250504.SGD","BK4611","LU0058720904.USD","BK4535","BK4588","LU1974910355.USD","LU0823434740.USD","LU0320765992.SGD","CRSP","LU2089984988.USD","BBH","IBBQ","LU0053666078.USD","LU0823434583.USD","LU0109394709.USD","EDIT","IBB","LU0114720955.EUR","TBXU","REGN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.editasmedicine.com","stockEarnings":[{"period":"1week","weight":-0.113},{"period":"1month","weight":-0.1804},{"period":"3month","weight":-0.2104},{"period":"6month","weight":-0.03},{"period":"1year","weight":-0.2642},{"period":"ytd","weight":0.2634}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0.0247},{"period":"6month","weight":0.1652},{"period":"1year","weight":0.1515},{"period":"ytd","weight":0.1207}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.048743},{"month":2,"riseRate":0.5,"avgChangeRate":0.075357},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.053873},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.002841},{"month":5,"riseRate":0.545455,"avgChangeRate":0.014988},{"month":6,"riseRate":0.545455,"avgChangeRate":0.075904},{"month":7,"riseRate":0.636364,"avgChangeRate":0.013826},{"month":8,"riseRate":0.636364,"avgChangeRate":0.049812},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.083382},{"month":10,"riseRate":0.4,"avgChangeRate":-0.058936},{"month":11,"riseRate":0.5,"avgChangeRate":0.071042},{"month":12,"riseRate":0.3,"avgChangeRate":0.023099}],"exchange":"NASDAQ","name":"Editas Medicine","nameEN":"Editas Medicine"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Editas Medicine(EDIT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Editas Medicine,EDIT,Editas Medicine股票,Editas Medicine股票老虎,Editas Medicine股票老虎国际,Editas Medicine行情,Editas Medicine股票行情,Editas Medicine股价,Editas Medicine股市,Editas Medicine股票价格,Editas Medicine股票交易,Editas Medicine股票购买,Editas Medicine股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Editas Medicine(EDIT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}